Rachel Klemovitch, Assistant Editor04.11.24
Ricoh 3D and SimBioSys, Inc. have joined a collaborative initiative to explore technologies with the potential to aid in the treatment of breast cancer. The goal of this collaboration is to help create a transformative approach to breast cancer treatment, integrating SimBioSys’ artificial intelligence (AI) capabilities with Ricoh’s 3D-printing expertise to produce accurate, patient-specific breast cancer models.
The collaboration will evaluate the potential of AI with 3D printing to help improve surgical experiences and personalize patient care for breast cancer.
Ricoh 3D for Healthcare and SimBioSys will unveil some of their first AI-generated, 3D-printed breast cancer models at the upcoming American Society of Breast Surgeons (ASBrS) conference.
Ricoh USA, Inc. Managing Director, Gary Turner told the press, “Through a collaboration with SimBioSys, we hope to not just envision a new future for medical treatment but help actively create it. Our dedication to precision and personalization in breast cancer care is about to be showcased at ASBrS, reflecting the potential of our combined efforts."
"Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made,” said SimBioSys Chief Commercial Officer, Jyoti Palaniappan.
SimBioSys is known for its TumorSight technology, the first digital precision medicine platform, and Ricoh, via its Ricoh 3D for Healthcare business, is a leader in the manufacturing of patient-specific medical devices.
The collaboration will evaluate the potential of AI with 3D printing to help improve surgical experiences and personalize patient care for breast cancer.
Ricoh 3D for Healthcare and SimBioSys will unveil some of their first AI-generated, 3D-printed breast cancer models at the upcoming American Society of Breast Surgeons (ASBrS) conference.
Ricoh USA, Inc. Managing Director, Gary Turner told the press, “Through a collaboration with SimBioSys, we hope to not just envision a new future for medical treatment but help actively create it. Our dedication to precision and personalization in breast cancer care is about to be showcased at ASBrS, reflecting the potential of our combined efforts."
"Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made,” said SimBioSys Chief Commercial Officer, Jyoti Palaniappan.
SimBioSys is known for its TumorSight technology, the first digital precision medicine platform, and Ricoh, via its Ricoh 3D for Healthcare business, is a leader in the manufacturing of patient-specific medical devices.